Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-2: subcutaneous ALKS 4230 alone and with pembrolizumab in advanced solid tumors
NL-OMON55159Phase 2Completed
- Sponsor
- Alkermes
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nemvaleukin alfa and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 5 more (5 arms), sponsored by Alkermes. Primary endpoints: Incidence and severity of treatment-emergent adverse events and Overall response rate. Started Dec 2021; status: completed.
02
Drugs
nemvaleukin alfapembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NL-OMON55159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55159.